Status:

COMPLETED

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Lead Sponsor:

Gilead Sciences

Conditions:

Metastatic Solid Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).

Detailed Description

This is a rollover study. Only participants who continue to receive clinical benefit from continuation of SG therapy and are tolerating therapy at the time of enrollment are eligible for this study. P...

Eligibility Criteria

Inclusion

  • Key
  • Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study.
  • Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy.
  • Key

Exclusion

  • Females who are pregnant or lactating.
  • Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated.
  • Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy.
  • Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

August 4 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 18 2024

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT04319198

Start Date

August 4 2020

End Date

October 18 2024

Last Update

September 30 2025

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

University of California San Francisco

San Francisco, California, United States, 94143

2

Rocky Mountain Cancer Center

Aurora, Colorado, United States, 80012

3

Christiana Care Health Services, Christiana Hospital

Newark, Delaware, United States, 19718

4

Florida Cancer Specialists & Research Institute

Fort Myers, Florida, United States, 33905

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | DecenTrialz